Vercise Genus^™ Deep Brain Stimulation System

Precision takes shape

Clinical Excellence

Vercise™ DBS systems are supported by dozens of studies with hundreds of patients showing the clinical benefits that the systems provide to patients globally.

Vercise DBS System robust clinical data video.

Key Resources for the Vercise Genus DBS System

Directions for use Indications, safety and warnings DBS product warranty (rechargeable) DBS product warranty (non-rechargeable)

Customer support

Reimbursement

Patient education

Request a sales rep

Key DBS Study Findings

The INTREPID study, the first multi-center, prospective, double blinded, randomized, sham-controlled trial for deep brain stimulation, demonstrated at patients’ one-year follow-up:

improvement in on-time¹ without troublesome dyskinesia

improvement in UPDRS III scores¹

improvement in quality of life¹

of programs used more than one contact¹

See the Vercise DBS Systems’ clinical data

DIRECT DBS Study

Multiple Independent Current Control (MICC) and directionality Yielded Optimal Stimulation Settings in 92% of Patients.²

Anodic Stimulation

Vercise DBS offers unique anodic stimulation capabilities that are demonstrated to improve efficacy and side effect threshold³.

Therapeutic Window

larger therapeutic window⁴ enabled with low pulse width settings combined with Cartesia 3D*

Precision Delivered

The Vercise Genus DBS System features directional and standard leads powered by Cartesia 3D.

Learn more about the Vercise Cartesia™ Directional Lead

Precision Made Personal

All of the system’s IPGs are full-body MR Conditional** and powered by Cartesia 3D directional programming.

Learn more about Vercise Genus IPGs

Precision in Hand

Personalize DBS programming with wireless Bluetooth® communication, intuitive directional steering controls and insightful clinical effect annotations.

Learn more about Vercise™ Neural Navigator programming capabilities